Futura Medical PLC - Guildford, Surrey-based pharmaceutical company - Receives European patent for erectile dysfunction treatment, MED3000, until 2040. Continues to pursue patent applications to provide wider patent protection. Chief Executive Officer James Barder says: "The allowance of this patent application further cements the intellectual property of MED3000, as we support our distributors' roll out of our fast acting topically applied gel for the treatment of erectile dysfunction available without a doctor's prescription across the world."
Current stock price: 43.70 pence, up 2.8% on Monday in London
12-month change: up 13%
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Futura Medical (FUM)